Archive for the ‘Health’ Category

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES EARLY DETECTION INNOVATION GRANTS

$4.5 Million in Grant Funding Expands New Alzheimer’s Early Detection and Healthcare System Preparedness Efforts

CARIBPR WIRE, GENEVA, SWITZERLAND, May 23, 2022 — The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced the recipients of a grant program aiming for early detection of cognitive symptoms. The early detection grants total $4.5 Million from 8 countries across North America, Europe, Asia, and Africa.

The grants are an initiative of the DAC Healthcare System Preparedness Project, which aims to advance how healthcare systems worldwide detect, diagnose, treat, and care for people with or at risk for Alzheimer’s.

Grantees are located throughout the US, Brunei, Kenya, Germany, Japan, Canada, Cuba, and Armenia. Several grants will focus on expanding cognition screening and training for primary care providers. Others are harnessing innovative technologies to utilize optometrists and pharmacists. This will expand the pool of frontline workers available to screen for early detection, and reduce the unnecessary use of  specialist care. Another deploys a mobile clinic to offer direct clinical support or equip digital tablets to volunteer workers to rapidly improve detection  rates.

According to George Vradenburg, Founding Chairman of the Board, Davos Alzheimer’s Collaborative, “Each grant will bring unique and measurable benefits to its local health system and community and, through DAC’s global learning network, will also spread their learnings broadly around the world. Finding new and innovative ways to advance early detection is paramount to improving healthcare systems’ abilities to provide better care today, and to prepare for the future availability of treatments.”

The grant application process was extensive, with DAC receiving 76 responses from 21 countries in two months. A diverse panel of experts, including a family member of an Alzheimer’s patient living with the disease, served as an independent review committee for these grants:

  • Tarun Dua (Global) – World Health Organization
  • Wendy Weidner (Global) – Alzheimer’s Disease International
  • Ricardo Allegri (Argentina) – University of Buenos Aires & World Dementia Council
  • Chirine Chehab (Lebanon) – American University Hospital of Beirut
  • Lori Frank (United States) – RAND Corporation & New York Academy of Medicines
  • Ryoji Noritake (Japan) – Health and Global Policy Institute
  • Terry Fulmer (United States) – John A. Hartford Foundation
  • Chandresh Harjivan (Canada) – Family member of an Alzheimer’s patient

“Early detection of cognitive decline is critical for patients and families and I am excited to see the Davos Alzheimer’s Collaborative tackling this challenge with their Health System Preparedness Initiative,” says Chandresh Harjivan, a family member of an Alzheimer’s patient. “I was honored to be asked to be part of such an esteemed review committee and am very happy that families living with the disease were part of the evaluation process.”

A summary of each grant can be found below.

About the Davos Alzheimer’s Collaborative

Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About DAC’s Healthcare System Preparedness Project

DAC’s Healthcare System Preparedness Project (DAC-SP) is funding innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis of Alzheimer’s through pilot projects and early detection grants. The pilot projects are: AdventHealth Central Florida, FL, USA; Municipality of Volta Redonda, State of Rio de Janeiro, Brazil; Alzheimer Scotland; University of the West Indies (UWI), Caribbean Institute for Health Research, Jamaica; Kobe University, Japan; INGER/National Institute of Geriatrics, Mexico; and, Indiana University School of Medicine/Indiana University Health, IN, USA. These initiatives are incorporated into DAC Learning Labs, a network of governments and public health and healthcare system leaders, to share best practices that can be scaled globally.

###

***PLEASE NOTE: Click here to view a recorded discussion with some of the grant recipients, in which over 500 global leaders from 53 countries tuned in to learn about early detection. Click here to be kept informed about updated information regarding the DAC initiative.

Davos Alzheimer’s Collaborative Early Detection Grants

Toronto Memory Program and RetiSpec (Canada)

This project implements the world’s first screening model that leverages collaboration between optometry and a local Alzheimer Society chapter to enable accessible identification of individuals at risk for Alzheimer’s disease and referral to a qualified clinician, facilitating a faster diagnosis. The two community-based entry points include: (1) optometry clinics, where individuals can receive a non-invasive RetiSpec retinal scan for early detection of Alzheimer’s disease; and (2) the Alzheimer Society of Toronto, where individuals can undergo cognitive assessment.

Ludwig-Maximillans University (Germany)

Partners with two Universities, a health and social care charity, and three industry partners to conduct three screening types on seniors in Germany. This study will identify the best screening method by offering digital cognitive assessments, SCD questionnaire screening, and blood AD biomarkers testing to different groups. This study will also generate a patient registry to enroll patients in the global cohort and clinical trials workstreams, establish a fluid biobank, and train Artificial Intelligence diagnostic systems to better analyze speech patterns.

University of Havana (Cuba)

Provides a two-month training to primary care providers to integrate tablet based cognitive assessments Brain Health Assessment (BHA). The care provider will be assisted by informants, meaning a family-member or other person close to the patient, to help primary care providers determine if a dementia diagnosis is warranted.

Avant Institute (US – Multiple States)

This project implements Cognivue Clarity, a self-administered 10-minute cognitive performance screening tool, to increase access to digital cognitive screening assessments in 20-30 Community Pharmacy Enhanced Services Network (CPESN) pharmacy sites across rural, urban, and underserved communities throughout the United States. This project provides training and onboarding for pharmacies to use Cognivue to screen patients and evaluate the results to make further recommendations and referrals.

Africa Mental Health Research and Training Foundation (Kenya)

This project redeploys existing volunteer staff in the Strengthening Responses to Dementia in Developing Countries (STRiDE) project and trains community health workers to screen 2,400 people aged 60 and above. Workers are equipped with tablets to conduct the screening Instrument for Dementia (CSI-D) cognitive assessment and informant interview, word list recall task, and Euro-Dementia scale. Ultimately, results will inform health system policy and practices in Kenya.

Alzheimer’s Care Armenia (Armenia)

This cognitive screening education programs utilizes a van that has been outfitted as a multidisciplinary mobile clinic to offer educational programs and work with local clinical staff to screen for cognitive issues using the Montreal Cognitive Assessment (MOCA). The program provides citizens who test positive for cognitive decline with healthcare resources and offers workshops to caregivers on providing support.

Advocate Aurora Health (US- Illinois)

This project aims to educate primary care providers on the importance of early cognitive screening and provide them with EPIC electronic health record-based digital testing tools to manage their patients efficiently. Clinicians get access to continuing education programming, eConsult support services, and participate in a monthly Project ECHO-type case conference to discuss topics on dementia.

Kobe City Pharmaceutical Association (Japan)

This project evaluates the value of pharmacy-based digital cognitive tests. It combines the cognitive test with a regular healthcare consultation to increase regular cognitive testing, the rate of early detection of cognitive decline, and timely and accurate diagnosis of dementia in local community-based healthcare system.

University of Washington (US- Washington)

This project expands the pilot site success of the Gerontological Society of America (GSA) Kickstart, Assess, Evaluate and Refer (KAER Toolkit, 2020 Edition) into a fully operational Cognition in Primary Care (CPC) protocol in seven new primary care clinics across the University of Washington. The CPC model includes provider education training and incorporates two validated tests, the Montreal Cognitive Assessment (MoCa) and the Ascertain Dementia 8-Item Informant Questionnaire (AD8), and a structured Cognitive Checklist. This model checks for comorbidities of dementia and provides guidance on follow-up counseling and referrals to community resources.

Demensia (Brunei)

This project will perform a pilot test of community screening and information in Senior Citizen Activity Centers, followed by a focus group discussion to select an initial paper-based cognitive assessment. The project will systematically involve communities at grassroots levels – senior citizen activity centres, engagement of village heads and community centres, targeting older people and those with dementia risk factors. Community links formed by the association are available for multisectoral support with this initiative. Other project activities also include training of field workers regarding community screening and cognitive assessment and training workshops for primary care (followed by relevant specialties).

American Academy of Physician Associates and Cleveland Clinic (US – Ohio)

Through partnership with The American Academy of Physician Assistants (AAPA), the Physician Associate (PA) Foundation, and Cleveland Clinic, this project develops cognitive assessment toolkit for non-specialist medical practitioners to be trained in administering screenings, interpreting results, communicating those results and offering additional provider and patient resources. The pilot implementation will be followed by outcomes reporting and dissemination of the toolkit to the network of PA schools and all Cleveland Clinic locations.

Institute for Healthcare Improvement (IHI) (US – Massachusetts)

This project uses a systems redesign approach, working with approximately eight teams across a range of settings on testing and measuring the results of intervention strategies that increase assessment rates. IHI will build and operate a learning community to encourage peer learning among participating teams, provide guidance, and teach scientific improvement methods to facilitate the teams’ testing. Project outputs include a prototype set of interventions, implementation guidance, and an associated measurement set that will be ready to share and scale more widely.

Click Here for More Information »

HWPL And Shincheonji Church Of Jesus Blood Donations Contribute To Stability Of Blood Supply

CaribPR Wire, WASHINGTON, D.C., Weds. May 11, 2022: Blood shortages due to COVID-19 are prevalent across the world. In January, the American Red Cross declared “a national blood crisis”, calling for an increase in donation. This blood crisis was called the worst shortage in over a decade, and it posed a significant risk to patient care.

In South Korea, 18,000 donors from Heavenly Culture, World Peace and Restoration of Light (HWPL) and Shincheonji Church of Jesus collaboratively donated blood during a two-week blood drive beginning April 18th. This joint blood drive was recorded as the largest single group blood donation in the country.

Namsun Cho, head of the Korean Red Cross Blood Services, said: “When the impact of the Omicron reached its peak, Shincheonji Church of Jesus launched a large scale of blood donation. It was like rain during a drought. We are surprised that the number of donors exceeded 6,000 in 3 days and more people participated. We appreciate their life-saving dedication.”

A donation of this magnitude is particularly impactful, as even a single blood donation can save up to three lives.

“They did a really great job in the life-sharing movement. This scale is equivalent to one army corps donating blood for a year. The number of blood donors is nearly four times the number in a normal day, a great help in overcoming the current blood supply crisis,” said an official from the Blood Services.

“We also appreciate the members of the Shincheonji Church of Jesus who participated in the nationwide plasma donation for the development of a treatment for COVID-19 back in 2020,” he added.

In South Korea, blood donation certificates are issued to blood donors that can be used for a reduced fee when paying for a future blood transfusion. All the donors of Shincheonji and HWPL gave their personal certificates to alleviate the financial burden of patients in need of a blood transfusion.

Efforts to aid in replenishing and protecting the blood supply were not limited to just South Korea, however. In Washington, DC, members of Shincheonji organized a blood drive to donate plasma and help accelerate the development of a cure for COVID-19. The campaign organized and actively participated in by the DC congregation of Shincheonji Church of Jesus included four mass blood and plasma drives. Drawing hundreds of donors, two of the blood and plasma drives were held at Children’s National Hospital and two were held at INOVA Hospital.

The heart of Shincheonji Church of Jesus is clearly shown in their dedication to continuing to help their surrounding communities despite their members having also suffered greatly during the pandemic. Aligned with the ideals of Shincheonji Church of Jesus, HWPL is carrying out long-term peace projects based on solidarity with civil society and international organizations in 193 countries. The priorities of both organizations make an ideal partnership as their members donate blood together, and this is evidenced by the impact of their joint effort.

EDITOR’S NOTE: A picture for use with this press release is available HERE

Click Here for More Information »

Innova Medical Group Forms Strategic Partnership with Attomarker to Accelerate COVID Immunity Testing

PASADENA, Calif., May 5, 2022 /PRNewswire-HISPANIC PR WIRE/ — Innova Medical Group, Inc., a global health screening and diagnostic innovator and a world leader in the manufacturing and distribution of COVID-19 rapid tests, along with Attomarker, a nanophotonic biochemical testing company spun from the University of Exeter in the United Kingdom, announced today that the two companies have formed a strategic partnership to expedite immunity testing for COVID and other diseases globally.

Innova Medical Group Logo

Attomarker’s CE marked and UK Medicines and Healthcare products Regulatory Agency (MHRA) accredited rapid COVID Antibody Immunity Test assesses an individual’s antibody levels and estimates when they will likely be on the edge of immunity; providing vital insight for patients and public health officials to better inform the timing of vaccine shots and other protective measures.

The device is the first of its kind to measure an individual’s immune response to a COVID-19 vaccination, booster, infection – or a combination of the immune triggers and is currently available in clinics in the UK and the Caribbean.

As part of the partnership, Innova Medical Group made a minority investment in Attomarker and will become an official distributor of its products. Innova’s commercial capability in the rapid test space will help stimulate the development of Attomarker’s unique, multiplexed platform technology to achieve advances in rapid point-of-care diagnostics and personalized medicine.

“We are excited about working with the Attomarker team to help them accelerate growth,” said Daniel Elliott, CEO of Innova Medical Group. “Adding a much-needed immunity test into Innova’s COVID rapid test portfolio strengthens the pandemic management solution we offer to our global customers.”

Attomarker’s immunity testing technology measures multiple biomarkers in blood and saliva to provide a personal profile for up to 20 tests in seven minutes. Forthcoming tests include biomarkers for liver health, food allergies and fertility.

“Attomarker’s technology has the potential to change healthcare diagnosis and treatment with a portfolio of near-patient rapid diagnostics that would lead to more effective clinical intervention,” added Todd Malan, MD, Chief Medical Officer of Innova. “Most immediately, as protection from previous COVID infections and vaccinations decline and boosters continue to roll out, Attomarker’s science-based COVID-19 Antibody Immunity Test will be a valuable tool for individuals to make science based personalized healthcare decisions.”

Professor Andrew Shaw, CEO and founder of Attomarker said, ”This strategic alliance with Innova delivers a big boost to the Attomarker vision to a truly global perspective. We look forward to bringing more rapid solutions to help clinicians optimize interventions and enable people to take greater control over their own health.”

About Innova Medical Group
Innova Medical Group is a global health screening and diagnostic innovator driven to dramatically improve health outcomes worldwide with equitable, high-value testing solutions. Our strategic and iterative approach enables us to create, build and deploy myriad accessible tests customized to meet and empower the user at their point of need. www.innovamedgroup.com

About Attomarker Ltd
Attomarker Ltd is a MedTech company which was formed as a result of ground-breaking work conducted by Professor Andrew Shaw and his research group at the University of Exeter. The Attomarker vision is to personalise diagnostics and medicine by creating the world’s best, most efficient, affordable and sustainable diagnostics platforms for near patient, home testing and mail away use. Attomarker offers a complete rapid near-patient diagnostics system and has an exciting product pipeline. www.attomarker.com

Logo - https://mma.prnewswire.com/media/1494814/Innova_tagline_blue_Logo.jpg

Click Here for More Information »

THE DAVOS ALZHEIMER’S COLLABORATIVE LAUNCHES INNOVATIVE EARLY DETECTION EFFORT

Seven Flagship Pilot Sites Aim to Measurably Increase Timely, Accurate Diagnosis of Alzheimer’s

  • Unique global collaboration to prepare health systems for a future with new Alzheimer’s treatments
  • Pioneering use of blood-based biomarkers with digital cognitive assessments in primary care
  • Innovative, culturally relevant methods that can scale in high, low-and middle-income countries

CARIBPR WIRE, New York, NY, May 3, 2022: The Davos Alzheimer’s Collaborative (DAC) today announced that people with or at risk of Alzheimer’s in six countries will soon have an opportunity to participate in a pilot program designed to increase access to early detection and diagnosis of the disease through the use of innovative new screening tools, which is an essential step to provide better care today, and to prepare for the future availability of treatments. DAC is launching seven pilot sites beginning this month in the US, Scotland, Jamaica, Japan, Mexico and Brazil.

“We are finding enormous appetite from healthcare systems around the world to prepare for future Alzheimer’s treatments, but first we must help healthcare systems adapt to early detection,” said George Vradenburg, Founding Chairman of the Board, Davos Alzheimer’s Collaborative, and Convener, The Global CEO Initiative on Alzheimer’s Disease. “By working directly with medical professionals, researchers, people at risk, and patients, these sites will utilize cutting-edge technology to change the way we deliver care, and help prepare healthcare systems to get the right treatments to the right patients at every stage of the disease.”

The pilot sites will use simple digital cognitive assessment tools to detect the signs of the disease early, and innovative blood biomarkers to help evaluate the cause of identified symptoms. The goal is to measurably increase rates of timely and accurate diagnosis to put people on the correct person-centered care pathways and mitigate the impact of Alzheimer’s disease on the individual and their family.

Digital cognitive assessments such as Linus Health’s Core Cognitive Evaluation, Cogstate’s Cognigram, and Cognivue’s Clarity will be made available to the pilot sites, reducing the need for broad neuropsychological testing, which is time consuming for patients and requires specialized physicians for administration. Digital cognitive assessments also mark a significant technological advance over paper-and-pencil tests in terms of reliability and objectivity. DAC program sites are training other healthcare professionals to administer the digital cognitive assessments. In some cases, it can be administered via a tablet in the patient’s home, marking a dramatic step forward in terms of access and ease-of-use.

The blood-based biomarker, known as the PrecivityAD™ test, is a technology developed by specialty diagnostics company, C2N (St. Louis, MO). The test will aid in the accurate diagnosis of Alzheimer’s disease, and reduce the need for expensive, hard-to-access, more advanced tests.

“We’re proud and excited to play a key role in DAC’s groundbreaking work to enable Alzheimer’s early detection on a global scale,” said Dr. Joel Braunstein, Co-Founder and CEO of C2N Diagnostics. “Harnessing the power of advanced diagnostics like our PrecivityAD test at DAC’s pilot sites will accelerate the fight to end Alzheimer’s.”

“DAC and the flagship pilot sites are driving new tools into the front lines of care. This is important to help patients today, and develop the data we need to better detect, treat and ultimately prevent this devastating disease,” said Stephen Friend, Founder and Chairman of the Board of Sage Bionetworks, Visiting Professor of Connected Medicine, and President 4YouandMe.

The pilot sites will provide localized care and treatment for individuals and develop models for broader healthcare systems to study and adopt. DAC Learning Labs, a network of governments, public health and healthcare system leaders, will provide a forum for sharing best practices that can be scaled globally.

About the Davos Alzheimer’s Collaborative

Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About DAC’s Healthcare System Preparedness Project

DAC’s Healthcare System Preparedness Project is funding innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis of Alzheimer’s. The pilot projects are: AdventHealth Central Florida, FL, USA; Municipality of Volta Redonda, State of Rio de Janeiro, Brazil; Alzheimer Scotland; University of the West Indies (UWI), Caribbean Institute for Health Research, Jamaica; Kobe University, Japan; INGER/National Institute of Geriatrics, Mexico; and, Indiana University School of Medicine/Indiana University Health, IN, USA. These initiatives are incorporated into DAC Learning Labs, a network of governments and public health and healthcare system leaders, to share best practices that can be scaled globally.

###

NOTE: To join an upcoming Learning Lab such as Meeting of the DAC Learning Laboratory: Driving Early Detection Across Aging Societies, planned for May 17, 2022, click here. This Lab will feature DAC healthcare system pilot sites and demonstrate the first of many collaborative exchanges championed through DAC’s initiatives.

Attachment

Click Here for More Information »

ASOFARMA CENTRAL AMERICA AND THE CARIBBEAN, THROUGH ITS HEADQUARTERS ADIUM, REACHES AN IMPORTANT AGREEMENT WITH MODERNA INC. TO COLLABORATE IN THE DISTRIBUTION AND MARKETING OF VACCINES AGAINST COVID 19 IN THE REGION

Leading company in pharmaceutical innovation, based in our country, signs unprecedented agreement for the arrival of vaccines against COVID-19

PANAMA CITY, Feb. 23, 2022 /PRNewswire-HISPANIC PR WIRE/ — ASOFARMA Central America and the Caribbean, through its parent company ADIUM, and Moderna Inc. reached a collaboration agreement for the distribution and commercialization in the region of SPIKEVAX, the vaccine developed by Moderna against SARS -CoV-2.

ASOFARMA Central America and the Caribbean is a leading pharmaceutical company in the region, which develops, produces and markets innovative products in therapeutic areas such as oncology, cardiology, central nervous system, diabetes and urology, among others.

As part of the agreement reached, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, continuing medical education, government affairs, marketing, and generation of new agreements that facilitate the availability of SPIKEVAX in the region.

“We are delighted to partner with Moderna to help patients, physicians and governments in this effort against COVID-19. Moderna is a leading company in the fight against the pandemic, and we are proud to have been chosen as partners for this task, providing all our experience and regional presence,” said Bernardo Girala, General Manager of ASOFARMA Central America and the Caribbean.

“This alliance confirms our purpose of providing the population with innovative treatments that help improve their quality of life and expand vaccination rates in the region,” Girala said.

Moderna Inc., a pioneer biotechnology company in the development of messenger RNA (mRNA) therapies and vaccines, has relied on ASOFARMA to make possible the arrival in the region of its vaccine against COVID 19, Spikevax.

Moderna’s mRNA platform is based on continuous advances in basic and applied mRNA science, delivery and manufacturing technology; which has allowed the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.

With this new agreement reached by ASOFARMA, Moderna Inc. joins a list of international pharmaceutical and biotechnological research and development companies that ASOFARMA has represented in the region for more than twenty years.

Photo - https://mma.prnewswire.com/media/1752293/ASOFARMA.jpg

Click Here for More Information »

Caribbean Nationals Wanted For Heart Study

CaribPR Wire, FORT LAUDERDALE, FL, Sat. Jan. 22, 2022: A US study is putting the spotlight on Afro-Caribbean nationals who have heart disease, or have been diagnosed with Transthyretin Amyloid Cardiomyopathy, (ATTR-CM).

Afro-Caribbeans with lived experiences can now share their story via a national, qualitative study and get paid if they are considered a good candidate.

The national study is intended to deepen understanding of Afro-Caribbean people suffering heart issues, including heart failure and related health conditions, such as high blood pressure, obesity, diabetes, etc.

“We are focused on the Afro-Caribbean community due to a higher prevalence of heart failure and specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM),” said Donna Fullerton, Research Partner at Now What. “It is well-established that the broader Black community is disproportionately affected by ATTR-CM, which is driving our attention here. We are looking to speak with, hear stories from, and understand the nuances within the Black community so that future communications and resources around disease awareness and treatment options will be culturally relevant and appropriate and hopefully lessen the health disparities we see today.”

To qualify, Afro-Caribbeans must be between ages 45-75, live in the US, and have been diagnosed with heart failure. Qualified participants will be paid $200 compensation for 2.5 hours of engagement, answering questions and completing activities over a computer or smartphone.

Participants who make the first round of the study, must also be open to take part in a follow-up 75-minute zoom call, for an additional $150.

If you feel you qualify, complete a short pre-qualification survey at: tinyurl.com/heartresearch before January 31st.

“The online exercises will ask people questions about their culture, their community, their thoughts about health and the healthcare system, and their experiences living with a heart condition,” added Fullerton. “All of our questions are designed to be respectful and empathetic – we only ask people to share what they are comfortable sharing and always respect people’s privacy.”

Heart diseases, such has coronary heart disease and heart failure, are more common in Blacks, than other ethnic groups — and so are the other cardiovascular diseases such as stroke and peripheral artery disease. Health issues like obesity, high blood pressure and diabetes can increase a person’s risk of heart failure. People of African heritage have higher rates of heart failure, hospitalization and death from the disease, according to national data.

Although care of patients with Heart Failure, HF, has improved in the past decade, important disparities in HF outcomes persist based on race/ethnicity. Recent scientific data shows that age-adjusted HF-related cardiovascular disease death rates are higher for Black patients, particularly among young Black men and women whose rates of death are 2.6- and 2.97-fold higher, respectively, than White men and women.

Similarly, the rate of HF hospitalization for Black men and women is nearly 2.5-fold higher when compared with Whites, with costs that are significantly higher in the first year after HF hospitalization.

While the relative rate of HF hospitalization has improved for other race/ethnic minorities, the disparity in HF hospitalization between Black and White patients has not decreased during the last decade.

The ultimate goal of this ongoing, targeted research is to learn from and speak with members of the Afro-Caribbean community so that future communications and resources around disease awareness and treatment options will be culturally relevant and appropriate, in order to hopefully lessen the health disparities currently.

EDITOR’S NOTE: A Photo for use with this story is available HERE

Click Here for More Information »

Miami Cancer Institute Becomes the First and Only APEx Accredited Proton Therapy Facility in the State of Florida

MIAMI, Sept. 20, 2021 /PRNewswire-HISPANIC PR WIRE/ – Miami Cancer Institute, part of Baptist Health South Florida, has been granted full accreditation by the ASTRO Accreditation Program for Excellence (APEx ®) for a four-year term effective August 10, 2021.  With this accreditation, Miami Cancer Institute is now one of only seven radiation oncology facilities in the state of Florida to have received this prestigious honor, and the first and only APEx accredited proton center in Florida.

This APEx accreditation validates that Miami Cancer Institute has and will continue to have systems, personnel, policies and procedures in place to demonstrate dedication to high-quality patient care, a respect for protecting the rights of patients, and being responsive to patient needs and concerns.

“APEx Accreditation represents certification by the most important professional body in Radiation Oncology, with the highest quality of safety and radiation oncology standards. To work at a cancer center that has gained this recognition is very rewarding, said  Dr. Minesh Mehta, Deputy Director and Chief of Radiation Oncology at Miami Cancer Institute.

“As we continue to advance the technology platforms that we use to treat our patients with, this accreditation is another reminder that Miami Cancer Institute continues as a leader in providing the best quality care for our patient community; in particular, the distinction of having the only proton center in our State to have reached this level of success, is particularly impressive,” shared Dr. Mehta. “Over the past 4 years, we have worked tirelessly as a multi-disciplinary team to provide our patients with state-of-the-art radiotherapy cancer care that is founded on evidence-based science, bolstered by continuous quality improvement initiatives, and administered using clinical best-practices”.

To learn more about the APEx Accreditation, you can learn more here. For the full list of accredited facilities, please feel free to visit this site.

About Miami Cancer Institute

Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK.

Miami Cancer Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, Instagram, Twitter and LinkedIn.

Click Here for More Information »

Doctors Hospital Advances Legal Action Around Hiring Institutionally Registered Medical Practitioners In The Cayman Islands, Claiming Patient Safety Is Otherwise At Risk

GEORGE TOWN, Cayman Islands, July 22, 2021 /PRNewswire-HISPANIC PR WIRE/ — Doctors Hospital has applied to the Grand Court in Cayman for leave for judicial review of the ongoing failure by the Government of the Cayman Islands (”the CIG”) to formulate and publish criteria against which healthcare facilities are assessed before being designated as a facility that may employ ‘institutionally registered’ medical practitioners.

Doctors Hospital’s central complaint is that the CIG has failed to formulate, publish and apply a transparent criteria for designating and supervising these facilities so the public can be assured there is adequate supervision of the less qualified and less experienced practitioners they employ.

In the absence of such criteria, Doctors Hospital claims, Cabinet’s power to designate a facility is liable to be exercised arbitrarily and in a way that fails to promote the purpose of institutionally registered practitioners only, being permitted to work at certain facilities.

A pre-action protocol letter was sent to the CIG on 23 April 2021, which asked it to “identify whether there are any criteria for granting and reviewing designations under s.24A(2)” of the Health Practice Act (2021 Revision).  The letter also asked to “confirm CIG commit to publishing criteria within a specified timeframe“. The Attorney General’s Office replied on 18 May 2021, admitting that:

(1)  there are no criteria, published or otherwise, for granting and reviewing designations,

(2)  CIG is unaware of the reasons why the only facilities designated to date (Health City, the Health Services Authority and Total Health Ltd) were granted designations, and

(3)  there are no arrangements for supervising the ongoing suitability of those facilities as places institutionally registered practitioners may practise.

By letter dated 18 June 2021, Doctors Hospital offered the CIG a final opportunity to commit to publishing criteria for granting and reviewing authorisations, failing which it would commence legal proceedings. No reply to that letter has been received.

Doctors Hospital accepts that the Legislature was entitled to introduce a tier of registration, whereby less qualified and less experienced practitioners are permitted to practice in the Cayman Islands. However, in creating a system where these practitioners may only work at facilities designated by Cabinet, the Legislature must have intended that these facilities will adequately supervise those practitioners.

Cayman Islands’ lack of regulation of doctors claiming to be “Specialists”

Doctors Hospital’s application also refers to the lack of any regulation setting the requirements to be met for institutionally registered practitioners to be registered as specialists in a particular field (such as oncologists or obstetricians). This lack of regulation risks patients being treated by insufficiently trained and inexperienced doctors without their knowledge, further risking potential harm to patients and the rising costs of health care via increased insurance premiums.

“As stated before, we believe in fair and competitive marketplaces,” says Dr Yaron Rado, Board Chairman and Chief Radiologist of Doctors Hospital. He added, “Further, we need this system to be transparent and safe for people engaging in healthcare in Cayman. We understand individuals are being granted institutional list registration for positions without completed residency programmes. This is alarming to us and should be alarming to everyone. To be registered as a specialist on the principal list, you need at least four years post-medical degree specialist training; to successfully sit a Board exam and then have completed three years post speciality experience to be licensed in Cayman. None of this is overseen on the institutional list. So we will continue to challenge the government about this.  Ultimately, what is at stake is the health and well-being of the people of Cayman and the standard of healthcare that the Islands deliver. To maintain high standards, Doctors Hospital has chosen only to employ fully registered practitioners who are on the principal list.”

About the system of ‘institutionally registered’ practitioners.

Similar to jurisdictions such as Singapore, the Cayman Islands has a tiered system of registering health professionals. Before being licensed to practice, practitioners must register on the ‘principal list’, the ‘provisional list’ or ‘the institutional list’. The law sets various criteria for being eligible for each list.

Practitioners registered on the principal list, deemed the most qualified and experienced, can practice without supervision;

Practitioners registered on the provisional list, deemed to be adequately qualified but lacking experience, must practice under the supervision of a practitioner on the principal list; and

Practitioners registered on the institutional list merely need to have qualified at a medical school listed in the World Directory of Medical Schools. This directory aims to list every medical school worldwide and admits that it is not an indicator of quality. These practitioners may be employed only by a health care facility Cabinet has designated as permitted.

The statutory scheme for institutional designation was introduced in 2011 and offered as an inducement by CIG to Narayana Hrudayalaya Private Limited, which owns and operates Health City, according to a contract dated 7 April 2010. The scheme came under renewed focus when on 21 December 2020, the CIG entered into a contract, with Aster Caribbean Holdings Ltd.  This contract included a commitment by CIG to use its best endeavours to secure the designation of the proposed Aster Cayman Medcity hospital (”ACMH”) as a place at which institutionally registered practitioners could practice.

On 19 April 2021, the Grand Court granted Doctors Hospital leave to apply for a judicial review of the lawfulness of CIG’s commitment to granting vast work permit fees, customs and stamp duty concessions to Health City and Aster Cayman MedCity. They argued that these “concessions unfairly distort competition between healthcare providers in the Cayman Islands and could ultimately compromise the quality of healthcare available.

Click Here for More Information »

Ryvex and SD Biosensor donate WHO approved COVID 19 antigen kits to Barbados and the OECS

MIRAMAR, Florida, March 15, 2021 /PRNewswire-HISPANIC PR WIRE/ – Ryvex, LLC (www.ryvex.net) in partnership with SD Biosensor (www.sdbiosensor.com) have donated over 20,000 rapid Antigen tests to the OECS member states and Barbados. The kits donated have been approved by the WHO. The kits are scheduled to arrive this week to the different beneficiary island nations.

Part of the donation being loaded for shipment to Barbados and the OECS member states

In response to the COVID-19 crisis, the donation will strengthen testing response at the country level, improve services delivery capacity, support initiatives to break the chain of transmission of the illness and improve case detection and management.

Testing is the key to getting back to normal. One of Ryvex’s goals is to contribute on finding solutions to help stop the spread of COVID-19, particularly among vulnerable populations that have been disproportionately affected by this pandemic.

Barbados seemed to have avoided a destructive COVID-19 pandemic. The Caribbean nation, home to around 287 000 people, registered fewer than 400 cases of the disease for the whole of 2020. But January, 2021, saw a surge. By the end of the month, Barbados had registered well over 1000 new cases of COVID-19. On Feb 3, 2021, it went into lockdown. On the same day, Saint Lucia, an OECS member state, declared a state of emergency. It has confirmed more than three times as many cases of COVID-19 this year as it did last year. Like Barbados, Saint Lucia has imposed a nightly curfew on its 180 000 or so residents. Community transmission of COVID-19 has also been established in other parts of the Caribbean, including Haiti, Jamaica, Saint Vincent and the Grenadines, and Trinidad and Tobago.

Ryvex remains committed in aiding with the efforts to contain the COVID19 pandemic in The Caribbean region through partnerships with public and private health institutions in the region.

Ryvex is the official distributor for SD Biosensor in The Caribbean region.

Photo - https://mma.prnewswire.com/media/1456359/Ryvex_antigen_kits.jpg

Click Here for More Information »

Dahua Technology Launches Retail Epidemic Safety Protection Solution To Enhance Store Operation Safety Under COVID-19

KINGSTON, Jamaica, July 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — A recent report from AP News shows that a lot of major non-essential retailers worldwide have been affected by COVID-19. According to Neil Saunders, Managing Director of GlobalData Retail, more than 190,000 stores have temporarily closed, accounting for nearly 50% of U.S. retail square footage. At the same time, Swedish fashion retailer H&M also implied that after temporarily closing 3,441 of its 5,062 stores globally, it may be forced to lay off some employees permanently. How to survive during the pandemic and take effective prevention and control measures after work resumption has become a major consideration for retailers across the globe.

In response to the challenges facing the retail industry, Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has launched a professional Retail Epidemic Safety Protection Solution to help retailers maintain safe operations and improve business efficiency during the pandemic, as well as providing upgraded plans to increase ROI after business resumption.

Featuring thermal body temperature monitoring and customer flow control, the Dahua Retail Epidemic Safety Protection Solution combines two technological advantages enabled by AI to provide double value for retailers, assisting in slowing the spread of the virus while creating a safe in-store shopping experience for customers.

The Dahua thermal body temperature monitoring camera allows highly accurate body temperature monitoring of ±0.3℃ (with blackbody). With built-in AI algorithm, it can simultaneously monitor a group of people from up to 3-meter distance, enabling fast and non-contact access. When installed at the entrances of supermarkets and shopping malls, it can help retailers with preliminary screening of employees and customers with abnormal body temperature. It notifies users to take corresponding measures before the temperatures change significantly, thereby enabling the appropriate protocol and conducting a second verification by medical professionals if necessary.

For retailers who require limited customer flow during the pandemic, the Dahua AI-empowered people counting camera can automatically and accurately calculate the real-time number of people entering the store, avoiding congestion and helping to mitigate the spread of the pandemic. When the number of shoppers exceeds the set value, the device will alarm and will display on the digital signage at the entrance of the store that the number of people inside is full, reminding customers to wait at the door. No extra employees are needed to count customers manually at the door, which can help retailers reduce labor costs and improve their management efficiency.

Excellent authorized store in Jamaica
Beauty Queen Plaza
13 Crane blvd Fairview Shopping Centre Montego Bay
Tel.: 876-631-7317

Photo - https://mma.prnewswire.com/media/1217051/Dahua_Technology.jpg

Click Here for More Information »

Correction in Total COVID-19 Deaths for Latin American and Caribbean Nations

SEATTLE, June 25, 2020 /PRNewswire-HISPANIC PR WIRE/ – An unintentional error in calculating total deaths for Latin America and the Caribbean resulted in IHME issuing an incorrect total for the region in a June 24 press release and on its website. The reported total of nearly 388,300 excluded Argentina, Chile and Uruguay. The updated total for Latin America and the Caribbean is 438,698 deaths. IHME regrets the error.

The forecasted deaths for individual nations are correct. IHME will continue to update as new data are available.

The forecasts can be viewed at https://covid19.healthdata.org.

Logo - https://mma.prnewswire.com/media/1156878/IHME_Logo.jpg

Click Here for More Information »

New IHME COVID-19 Model Forecasts Latin American, Caribbean Nations Will See Nearly 388,300 Deaths by October 1

SEATTLE, June 24, 2020 /PRNewswire-HISPANIC PR WIRE/ – The Institute for Health Metrics and Evaluation (IHME) at the University of Washington is forecasting nearly 388,300 people will die from COVID-19 in Latin American and Caribbean nations by October 1.

Brazil is expected to exceed 166,000 deaths and Mexico 88,000. Six other nations are each predicted to exceed 10,000: Argentina, Chile, Colombia, Ecuador, Guatemala, and Peru. In contrast, 15 nations, including Paraguay, Uruguay, and Belize are each expected to have fewer than 1,000 deaths.

“Several Latin American countries are facing explosive trajectories, while others are containing infections effectively,” said IHME Director Dr. Christopher Murray. “I cannot overemphasize the imperative of mitigation measures, such as mask wearing and social distancing, especially since South American nations are facing increasing infections due to seasonality of COVID-19, an important factor contributing to the transmission of the virus.”

IHME’s new forecasts model deaths from the virus if countries impose social distancing mandates for six weeks at the point when deaths reach 8 per million people, comparing that to a scenario if no action is taken. The percentage of people wearing masks when leaving their home is also a key consideration.

“These factors are vital in our projections and highlight how many lives can be saved,” Murray said.

He noted that the number of deaths is certain to continue to rise in nations where mandates on mask wearing and social distancing are relaxed. In contrast, Murray stated transmission might be reduced by as much as 50% in communities where individuals are wearing masks when leaving their homes, either voluntarily or by mandate.

The forecasts by nation:

Southern, Tropical, and Andean Latin America

  • Argentina: 24,721 deaths (range of 9,386 to 61,163)
  • Chile: 25,344 deaths (range of 18,094 to 34,509)
  • Uruguay: 340 deaths (range of 52 to 2,075)
  • Bolivia: 7,334 deaths (range of 3,564 to 13,645)
  • Ecuador: 20,260 deaths (range of 16,069 to 27,103)
  • Peru: 36,210 deaths (range of 28,145 to 48,617)
  • Brazil: 166,362 deaths (range of 135,538 to 208,079)
  • Paraguay: 271 deaths (range of 27 to 1,952)

Central America and Mexico

  • Colombia: 35,314 deaths (range of 14,640 to 81,942)
  • Costa Rica: 39 deaths (range of 17 to 120)
  • El Salvador: 4,357 deaths (range of 668 to 15,546)
  • Guatemala: 10,090 deaths (range of 3,874 to 22,071)
  • Honduras: 4,958 deaths (range of 881 to 14,207)
  • Mexico: 88,160 deaths (range of 67,967 to 120,023)
  • Nicaragua: 280 deaths (range of 72 to 2,276)
  • Panama: 2,802 deaths (range of 1,315 to 5,895)
  • Venezuela: 2,893 deaths (range of 84 to 29,295)

The Caribbean

  • Antigua and Barbuda: 10 deaths (range of 2 to 74)
  • Bahamas: 26 deaths (range of 10 to 121)
  • Barbados: 46 deaths (range of 8 to 282)
  • Belize: 20 deaths (range of 3 to 143)
  • Cuba: 306 deaths (range of 180 to 663)
  • Dominican Republic: 5,665 deaths (range of 1,731 to 15,650)
  • Guyana: 14 deaths (range of 12 to 24)
  • Haiti: 1,377 deaths (range of 202 to 5,919)
  • Jamaica: 68 deaths (range of 17 to 364)
  • Suriname: 698 deaths (range of 28 to 2,541)
  • Trinidad and Tobago: 440 deaths (range of 13 to 6,868)
  • Puerto Rico: 286 deaths (range of 185 to 605)
  • United States Virgin Islands: 7 deaths (range of 6 to 11)

The new death projections and other information, such as hospital resources usage, are available at https://covid19.healthdata.org.

Contact: media@healthdata.org

A note of thanks

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible: ACAPS; American Hospital Association; Bill & Melinda Gates Foundation; Blavatnik School of Government, University of Oxford; Bloomberg Philanthropies; Boston Children’s/Health Map; California Health Care Foundation; Carnegie Mellon University; Christopher Adolph and colleagues at the Department of Political Science, University of Washington; Descartes Labs; Facebook Data for Good; Google Labs; John Stanton & Theresa Gillespie; Julie & Erik Nordstrom; Kaiser Family Foundation; Medtronic Foundation; Microsoft AI for Health; National Institute on Minority Health and Health Disparities (NIMHD) at the National Institutes of Health (NIH); National Science Foundation; Our World in Data; Premise; Qumulo; Real Time Medical Systems; Redapt; SafeGraph; The COVID Tracking Project; The Johns Hopkins University; The Kuwait Foundation for the Advancement of Sciences (KFAS); The New York Times; UNESCO; University of Maryland; University of Miami Institute for Advanced Study of the Americas (Felicia Knaul and Michael Touchton); Wellcome Trust; World Health Organization; and finally, the many Ministries of Health and Public Health Departments across the world, collaborators and partners for their tireless data collection efforts. Thank you.

About the Institute for Health Metrics and Evaluation

The Institute for Health Metrics and Evaluation (IHME) is an independent global health research organization at the University of Washington School of Medicine that provides rigorous and comparable measurement of the world’s most important health problems and evaluates the strategies used to address them. IHME is committed to transparency and makes this information widely available so that policymakers have the evidence they need to make informed decisions on allocating resources to improve population health.

Logo - https://mma.prnewswire.com/media/1156878/IHME_Logo.jpg

Click Here for More Information »

Baptist Health Unveils New Safety Measures as Elective Surgeries and Procedures Resume

New Steps Geared Towards Protecting Patients and Employees

MIAMI, May 20, 2020 /PRNewswire-HISPANIC PR WIRE/ — Baptist Health South Florida has announced new comprehensive safety guidelines as it welcomes back more patients and ramps up operations to fully restore in-person health services system wide. As Baptist Health resumes elective surgeries and procedures, enhanced safety precautions have been introduced to prevent the spread of infection and to ensure every facility including emergency rooms, urgent care centers and physician offices can safely care for patients who need healthcare.

In an effort to promote safety, cleanliness and social distancing, here are some of the changes patients, employees and visitors can now expect at Baptist Health facilities:

  • Enhanced Cleaning of High-touch Areas
  • Universal Mask Use
  • Contactless Registration
  • Point-Of-Entry Screening
  • Wait Where You Feel Comfortable, including in some cases, in your car
  • Hand-sanitizing Stations
  • Touch-free sliding doors
  • COVID-19 Patients Treated in Separate Area
  • Front Desk Plexiglass partitions
  • Social Distance Floor Markings
  • Chairs Spaced Out
  • Magazines Removed from Tables
  • Coffee and Snack Service Suspended

“As one of the leading healthcare providers in the region, our patients and employees have come to expect the highest standards in health and safety from us,” said Bo Boulenger, Executive Vice President and Chief Operating Officer at Baptist Health South Florida. “Now more than ever, our patients rely on our care and we are ready to care for them, especially those who may have delayed treatment during the pandemic. Through these steps, we are confident we can protect our patients and employees as we safely care for our community.”

These safety measures are based on information from the Centers for Disease Control and Prevention, the World Health Organization, the American Hospital Association, the Florida Governor’s Office and the White House’s Opening Up America Again guidelines.

For more information on Baptist Health’s safety plan, visit our Patient and Visitor Safety page at https://baptisthealth-coronavirus.com/patients-and-visitors.

About Baptist Health South Florida

Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Photo - https://mma.prnewswire.com/media/1170894/Baptist_Health_Because_We_Care_Safety_First_INFOGRAPHIC.jpg

Click Here for More Information »

Prominent neurosurgeon Michael McDermott, M.D., joins Baptist Health South Florida to lead Miami Neuroscience Institute

CORAL GABLES, Florida, April 30, 2020 /PRNewswire-HISPANIC PR WIRE/ — Baptist Health South Florida welcomes Michael McDermott, M.D., a world-renowned leader in neurosciences with clinical expertise in the field of meningioma research and gamma knife radiosurgery, as its new chief medical executive of Miami Neuroscience Institute, formerly known as Baptist Health Neuroscience Center.

Dr. McDermott, widely known for advancing neurosurgical techniques, pioneered surgical management of meningioma, a slow-growing tumor in the head that affects the brain. He is an expert in the treatment of a wide variety of neurological disorders, in addition to meningiomas, skull base tumors, brain metastases, gliomas, hydrocephalus, central nervous system infections and complex tumors of the skull base and spinal cord.

“I am delighted to have a colleague of his caliber join our organization,” said Michael Zinner, M.D., chief executive officer and executive medical director at Miami Cancer Institute, part of Baptist Health South Florida. “His expertise will help enhance our collaborative and interdisciplinary approach to research and delivery of the best cancer treatments for our patients.”

Dr. McDermott has conducted leading research that generated more than 400 peer-reviewed publications and comes from the University of California San Francisco (UCSF) Medical Center, ranked by U.S. News & World Report as third in the nation in neurology and neurosurgery, where he was co-director of the Gamma Knife and CyberKnife Radiosurgery Program and held the distinguished Wolfe Family Endowed Professorship in Meningioma Research. In addition to serving as professor and vice chairman of neurological surgery, he is an accomplished educator. As residency program director, he trained young physicians from around the world.

“The arrival of Dr. McDermott to lead Miami Neuroscience Institute represents Baptist Health’s ability to harness the collective expertise of physician leaders and to offer the most innovative, comprehensive and individualized care available to our patients,” said Jack Ziffer, PhD, M.D., executive vice president, chief clinical officer and chief physician executive for Baptist Health South Florida.

Miami Neuroscience Institute provides care at all the Baptist Health facilities, with the exception of Boca Raton Regional Hospital, home to the renowned Marcus Neuroscience Institute, and Bethesda Hospital East and Bethesda Hospital West’s neuroscience programs. For the first several months, Dr. McDermott will focus on working with clinical and administrative leadership to plan and build the infrastructure as well as clinical depth and breadth of the program and set the stage for growth as a destination for neuroscience care.

“The multidisciplinary team approach we have at Baptist Health creates a special synergy between medical specialists from various fields to provide the most advanced care to our patients. This exceptional physician and surgeon will complement the tremendous medical talent that resides within Baptist Health and will continue to grow our national leadership in the treatment of conditions of the brain, spine and nervous system,” added Dr. Ziffer, PhD, M.D.

Miami Neuroscience Institute

Miami Neuroscience Institute, formerly known as Baptist Health Neuroscience Center, offers comprehensive and compassionate treatment for neurological conditions affecting the brain, spinal cord and peripheral nervous system. From non-surgical treatments and minimally invasive procedures to complex brain and spine surgery, the Center embraces a multidisciplinary approach to patient care.

Miami Neuroscience Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Click Here for More Information »

Baptist Health International Cayman Islands PET & CT Imaging Center Receives Prestigious Recognition for Superior Patient Care

The Imaging Center was awarded the Gold Seal of Approval from the Joint Commission International (JCI), the first for Baptist Health South Florida outside the U.S.

The accreditation recognizes the Center for its high quality and standards in patient care.

GEORGE TOWN, Cayman Islands, March 12, 2020 /PRNewswire-HISPANIC PR WIRE/ – Baptist Health International Cayman Islands PET & CT Imaging Center, part of Baptist Health South Florida, was awarded the Gold Seal of Approval from the Joint Commission International (JCI), a global leader in accrediting quality in healthcare. This is the first JCI accreditation for Baptist Health South Florida outside the U.S. and positions the Imaging Center as one of the prestigious facilities around the world that are dedicated to achieving the highest standards in quality and safety in patient care.

“This recognition is a testament to our long-standing commitment to providing our patients in the Cayman Islands and the Caribbean with superior care when it comes to their health,” said Rogelio E. Ribas, corporate vice president of Baptist Health International. “We look forward to continuing the enhancement of our services and technology so that patients can have access to quality diagnostic imaging services and transforming the Cayman Islands into a top medical destination in the region.”

Accreditation was awarded following a detailed and comprehensive on-site survey and evaluation process, ensuring that the Imaging Center met the criteria in every area. JCI’s stringent standards – addressing topics such as patient education, qualification and competency of staff, the use of data to improve services and preparedness for emergencies – are updated regularly to reflect the advances in healthcare.

Baptist Health International Cayman Islands PET & CT Imaging Center is equipped with state-of-the-art positron emission tomography (PET) and computed tomography (CT) technology. It provides the latest solutions in diagnostic imaging, servicing patients not only in the Cayman Islands, but also those in other Caribbean countries who may not have access to these advanced technologies in their counties. Since its opening in 2019, the Imaging Center has provided more than 400 patients with diagnostic consults, reducing the need to travel abroad for a PET or CT scan.

About Baptist Health International
Baptist Health International is one of the largest hospital-based international programs in the United States, with more than 12,000 international patient visits at Baptist Health South Florida facilities from the Florida Keys to Palm Beach County. Baptist Health International is dedicated to providing comprehensive, high-quality services for international physicians and their patients, including hospital admissions, outpatient medical exams, medical second opinions and physician consultations, as well as concierge services.

About Baptist Health South Florida
Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune magazine as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Click Here for More Information »

Miami Cardiac & Vascular Institute Names Joseph T. McGinn, Jr., M.D., chief of Cardiac Surgery

MIAMI, March 4, 2020 /PRNewswire-HISPANIC PR WIRE/ — Miami Cardiac & Vascular Institute, part of Baptist Health and the region’s largest and most comprehensive cardiovascular facility, has named Joseph T. McGinn, Jr., M.D., chief of Cardiac Surgery. Dr. McGinn specializes in the assessment and surgical treatment of patients with coronary artery, aortic and vascular disease.  A pioneer in the field of cardiothoracic surgery, he developed the minimally invasive coronary artery bypass grafting method known internationally as the “McGinn Technique.”

Dr. McGinn comes to Miami Cardiac & Vascular Institute from Sanger Heart & Vascular Institute, part of Atrium HealthCare in Charlotte, North Carolina, where he served as endowed chair of Cardiovascular and Thoracic Surgery and professor of Cardiovascular and Thoracic Surgery. Prior to that appointment, he was a leading cardiac surgeon in New York City and served as medical director of the Heart Institute at Staten Island University Hospital for 16 years.

“Dr. McGinn is an expert physician and surgeon and an exceptional leader who has demonstrated excellence in patient care, innovation and team building,” said Barry T. Katzen, M.D., founder and chief medical executive of Miami Cardiac & Vascular Institute. “He will complement our team of highly skilled experts, who are committed to achieving the same goals.”

Jack A. Ziffer, Ph.D., M.D., executive vice president and chief clinical officer of Baptist Health South Florida, added, “We are pleased to have Dr. McGinn join Miami Cardiac & Vascular Institute in this leadership capacity to continue his groundbreaking work and further advance the Institute’s worldwide leadership position in the delivery of cardiovascular care.”

An accomplished educator, Dr. McGinn has trained hundreds of surgeons from around the world in minimally invasive cardiothoracic surgical techniques. His clinical and research efforts have generated hundreds of presentations at scientific symposiums and publications in peer-reviewed medical journals and books. He has been recognized by the American Heart Association for excellence in medicine and received the Samuel L. Koontz Award for Clinical Excellence. He is a Fellow of the American College of Cardiology, the American College of Chest Physicians and the American College of Surgeons and a member of numerous professional societies.

Dr. McGinn earned his medical degree at the State University of New York (SUNY) Downstate Medical Center College of Medicine. He completed an internship and residency in general surgery at SUNY Downstate, serving as chief resident. He also served as chief resident during a cardiothoracic surgery residency at Long Island Jewish Medical Center. He is board certified by the American Board of Surgery, American Board of Thoracic Surgery and the American Board of Surgery, Surgical Critical Care.

Dr. McGinn enjoys boating with his family and is an avid football fan. He has performed 1,500 MICS CABG cases.

About Miami Cardiac & Vascular Institute
Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. The Institute leverages the power of Baptist Health’s combined resources of experts, pioneering research, compassionate caregivers and leading-edge treatments and technology.

Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Photo - https://mma.prnewswire.com/media/1099414/McGinn_headshot.jpg

Click Here for More Information »

Expression Of Support For The Bahamian Community

MIAMI, Sept. 6, 2019 /PRNewswire-HISPANIC PR WIRE/ – In light of the devastating impact of Hurricane Dorian on the Bahamas, Baptist Health South Florida would like to share its deepest sympathy for the Bahamian people.

Baptist Health is taking immediate action to provide support as aid efforts begin. Rose Rahming, Baptist Health’s local representative in the Bahamas, is assisting with the coordination of relief efforts from the National Emergency Operations Centre as well as the Baptist Health International office in Nassau.

Baptist Health South Florida is working with the Bahamian authorities to provide a significant amount of medical supplies to the functioning hospital in the region, Princess Margaret Hospital located in Nassau. Baptist Health has also notified Bahamian authorities that we are prepared to support patient transfers for those affected by the storm.

Locally, we have partnered with South Florida-based Operation Helping Hands, which has been activated by United Way of Miami-Dade, to provide disaster relief to our Bahamian neighbors and friends in this critical time of need.

In the aftermath of a hurricane of this magnitude, financial contributions are critical to providing the most effective help to address the immediate needs of the affected areas. Operation Helping Hands ensures that the funds are used by organizations with the experience and infrastructure to deliver the immediate assistance needed. One hundred percent of the funds raised through Operation Helping Hands will go directly to those affected by Hurricane Dorian in the Bahamas.

For over two decades, Baptist Health has cultivated close friendships with our neighbors in the Bahamas. Although the road to recovery will be long, we stand ready and committed to assist the Bahamian people in the days, weeks, and months ahead.

About Baptist Health South Florida
Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to our faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

About Baptist Health International
Baptist Health International is one of the largest hospital-based international programs in the United States. Thousands of people travel to Miami each year from around the world to receive care from the renowned physicians at Baptist Health South Florida facilities. Baptist Health International is dedicated to facilitating comprehensive, high-quality services for international physicians and their patients, including hospital admissions, outpatient services and medical exams, second opinions, physician consultations and concierge services. For more information, visit BaptistHealth.net/International.

Click Here for More Information »

If you paid for Solodyn®, a class action lawsuit may affect your rights

NEW YORK, Dec. 13, 2017 /PRNewswire-HISPANIC PR WIRE/ – You may be affected by a class action lawsuit against Medicis Pharmaceutical Corp., and Impax Laboratories, (”Defendants”). The lawsuit claims that Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Solodyn and that Defendants’ conduct caused certain consumers and third-party payors (discussed below) to pay too much for Solodyn in these states and territories. Defendants deny any wrongdoing.

ARE YOU AFFECTED?

As a consumer, you may be a member of the End-Payor Class if after July 23, 2009 you purchased or paid for some or all of the purchase price for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions of one or more of these dosages, in the United States and its territories, including Puerto Rico, in tablet form, for consumption by yourself or your family. Purchases made directly from Defendants, for resale purposes, for fixed dollar co-payments that do not vary between brand and generic drug, through Medicaid, or consumers who purchased Solodyn prior to July 23, 2009 are not included.

YOUR RIGHTS AND OPTIONS

DO NOTHING : If you do nothing you are choosing to stay in the End-Payor Class and you will be able to share in any money or benefits that may occur in this case. You will be bound by all orders and judgments of the Court and you will give up your right to sue the Defendants as part of any other lawsuit for the claim made in this case.

EXCLUDE YOURSELF FROM THE END-PAYOR CLASS : If you exclude yourself from the End-Payor Class (i.e. opt out), you will not be entitled to money or benefits if they are awarded or obtained. You will be bound by all orders and judgments of the Court and you will give up your right to sue the Defendants as part of any other lawsuit for the claim made in this case. The deadline to exclude yourself from the End-Payor Class is February 10, 2018.

THE TRIAL

The Court will hold a trial in this case on March 12, 2018 at the United States District Court for the District of Massachusetts, 1 Courthouse Way Boston, Massachusetts 02210. You may hire your own lawyer at your own expense, but you do not have to.

WANT MORE INFORMATION?

Go to www.SolodynCase.com, call 1-800-332-7414, or write to In re Solodyn Antitrust Litigation (End-Payor Action), P.O. Box 173034, Milwaukee, WI 53217.

800-332-7414
www.SolodynCase.com

Click Here for More Information »

Henry Schein Disaster Relief Hotline Remains Open To Support Customers Affected By Hurricane Maria

Dentists, Physicians, and Veterinarians Who May Experience Operational, Logistical, or Financial Issues Encouraged to Call 800-999-9729

MELVILLE, N.Y., Sept. 20, 2017 /PRNewswire-HISPANIC PR WIRE/ – Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in Puerto Rico, the Caribbean, and all areas in the projected path of Hurricane Maria, that the Henry Schein Disaster Relief Hotline is open for dentists, physicians, and veterinarians who may experience operational, logistical, or financial issues as a result of damage caused by the storm.

The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to 7 p.m. ET.  The Henry Schein Disaster Relief Hotline remains open throughout the year to provide assistance to practitioners during their preparation and recovery from disasters.

To help meet the challenges of rebuilding a practice in the wake of a natural disaster, practitioners can download our Recovery Guide for Office-Based Practitioners and visit our Road to Recovery Resource Center for more resources and information.

“Our thoughts and prayers are with the people and communities of Puerto Rico, the Caribbean, and all areas preparing for Hurricane Maria’s potential impact,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “We encourage health care providers whose practices may sustain damage during the storm to contact our disaster relief hotline and visit our web-based Road to Recovery Resource Center for assistance in reopening their practices as soon as possible.”

About Henry Schein Cares
Henry Schein Cares stands on four pillars: engaging Team Schein Members to reach their potential, ensuring accountability by extending ethical business practices to all levels within Henry Schein, promoting environmental sustainability, and expanding access to health care for underserved and at-risk communities around the world. Health care activities supported by Henry Schein Cares focus on three main areas: advancing wellness, building capacity in the delivery of health care services, and assisting in emergency preparedness and relief.

Firmly rooted in a deep commitment to social responsibility and the concept of enlightened self-interest championed by Benjamin Franklin, the philosophy behind Henry Schein Cares is a vision of “doing well by doing good.” Through the work of Henry Schein Cares to enhance access to care for those in need, the Company believes that it is furthering its long-term success. “Helping Health Happen Blog” is a platform for health care professionals to share their volunteer experiences delivering assistance to those in need globally. To read more about how Henry Schein Cares is making a difference, please visit our blog: www.helpinghealthhappen.org.

About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein employs more than 21,000 Team Schein Members and serves more than 1 million customers.

The company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 32 countries. The company’s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.

Click Here for More Information »

Oxitec’s Friendly™ Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment

RIVM concludes negligible risk of Oxitec’s Friendly™ Aedes mosquitoes

France’s High Council for Biotechnology also publishes Supportive Position

OXFORD, England, July 12, 2017 /PRNewswire-HISPANIC PR WIRE/ –The National Institute of Public Health and the Environment (RIVM) in the Netherlands today published its “Technical evaluation of a potential release of OX513A Aedes aegypti mosquitoes on the island of Saba“, which positively concludes a vector control program using Oxitec’s Friendly™ Aedes aegypti mosquitoes would pose negligible risks to human health and the environment.

(Logo: http://photos.prnewswire.com/prnh/20150630/227348 )

RIVM’s GMO office undertook its biosafety evaluation of Oxitec’s Friendly™ self-limiting mosquito technology following the guidance for risk assessment of genetically modified animals by the European Food Safety Authority (EFSA) and the European risk assessment framework, which is considered one of the most robust and thorough biosafety frameworks globally.  Additionally this independent review reflected guidance from the World Health Organization (WHO) for testing of genetically modified mosquitoes as well as the Cartagena Protocol on the Biosafety to the Convention on Biological Diversity.

“We welcome the favorable outcome of the RIVM’s extensive review indicating a positive safety profile of our bio-based mosquito technology,” said Mark Carnegie-Brown Chief Executive Officer at Oxitec. “When combined with our excellent efficacy data, this result points to the significant potential of the Oxitec platform to safely address the growing global challenge from dangerous Aedes aegypti mosquitoes. We are committed to working with regulators worldwide to bring this important technology to market.”

This result reinforces the affirmative biosafety profile of Oxitec’s self-limiting technology for deployment in vector control programs, and also supports the conclusions of environmental assessments conducted elsewhere including from Brazil’s National Technical Commission of Biosafety (CTNBio) and the U.S. Food and Drug Administration (FDA) whose review team consisted of experts from the Center for Veterinary Medicine, the Centers for Disease Control and Prevention, and the Environmental Protection Agency.

Additionally, France’s High Council for Biotechnology (HCB) last month published its supportive position on the use of genetically modified mosquitoes for vector control, following the emergence of mosquito-borne diseases in French overseas territories and perceived threats to metropolitan France. Oxitec has been working closely with the HCB to help inform their evaluation and welcomes HCB’s opinion on self-limiting Aedes aegypti. The HCB opinion will help to shape the policy landscape in France towards the deployment of new tools for vector control, and is a positive step towards advancing Oxitec vector control projects in the French Caribbean.

How Friendly™ Aedes works

Oxitec has been working in Aedes aegypti control for over a decade and pioneered the use of a biological method to suppress wild populations of this dangerous mosquito species through the release of Friendly™ Aedes males, which do not bite and do not transmit diseases. When released, these males search for wild females to mate, and their offspring inherit a self-limiting gene that causes them to die before reaching functional adulthood.  Friendly™ Aedes’ offspring also inherit a fluorescent marker that allows tracking and monitoring at a level never before achieved, making the assessment of effectiveness more accurate throughout the whole Friendly™ Aedes deployment program. Unlike other approaches, Friendly™ Aedes mosquitoes die along with their offspring, and therefore do not persist in the environment or leave any ecological footprint.

About Oxitec

Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.  Follow us on Twitter at @Oxitec.

Click Here for More Information »